Role of combined therapy with β‎₂-agonists and anti­cholinergic drugs in bronchial asthma

1. Авдеев С.Н. Роль антихолинергических препаратов при обструктивных заболеваниях легких. Consilium Medicum 2002; 4 (9): 478-485.

2. Цветкова О.А., Белов А.А., Буянова О.Е. и др. Эффективность и безопасность терапии атровентом и беродуалом у больных хронической обструктивной болезнью легких в сочетании с ишемической болезнью сердца. Пульмонология 2002; 3: 100-106.

3. Чучалин А.Г., Медников Б.Л., Белевский А.С. и др. Бронхиальная астма. Руководство для врачей России. (Формулярная система). Пульмонология 1999; Прил.: 3-40.

4. Шмушкович Б.И. Бета-адренергическая рецепция у больных бронхиальной астмой. Механизмы десенситизации. В кн.: Чучалин А.Г. (ред.). Бронхиальная астма. М.: Агар; 1997. 118-134.

5. Aaron S.D. The use oi ipratropium bromide for the management of acute asthma exacerbation in adults and children: a systematic review. J. Asthma 2001; 38: 521-530.

6. Avdeev S., Aisanov Z., Chuchalin A. Compliance as a critical issue in long-term oxygen therapy. Arch. Monaldi Chest Dis. 1999; 54: 61-66.

7. Barnes P.J. Theoretical aspects of anticholinergic treatment. In: Gross N.. ed. Anticholinergic therapy in obstructive lung disease. London: Franklin Scientific Publication; 1993: 88-104.

8. Bauer R., Banholzer R. Pharmacology of quaternary anticholinergic drugs. Ibid. 104-115.

9. Bonsignore G., Bellia V., Peralta G. et al. The combination of fenoterol and ipratropium bromide in bronchial asthma: comparison of the acute effects of two different dosages. Respiration 1986; 50 (suppl.2): 148-151.

10. Brodde O.E., Schuler S., Kretsch R. et al. Regional distribution of beta-adrenoreceptors in the human heart: coexistance of functional betal- and beta2-adrenoceptors in both atria and ventricules in severe congestive cardiomyopathy. J. Cardiovasc. Pharmacol. 1986; 8: 1235-1242.

11. Brophy C., Ahmed B., Bayston S. et al. How long should Atrovent be given in acute asthma? Thorax 1998; 53: 363-367.

12. Bryant D.H. Nebulized ipratropium bromide in the treatment of acute asthma. Chest 1985; 88: 24-29.

13. Catterall J.R., Rhind G.B., Whyte K.F. et al. Is nocturnal asthma caused by changes in airway cholinergic activity? Thorax 1988; 43: 720-724.

14. Chrischilles E., Gilden D., Kubisiak J. et al. Delivery of ipratropium and albuterol combination therapy for chronic obstructive pulmonary disease: effectiveness of a two-in-one inhaler versus separate inhalers. Am. J. Manag. Care 2002; 8: 902-911.

15. Cochrane G.M. Compliance in athama. Eur. Respir. Rev. 1998; 8 (56): 239-242.

16. Crane J. Single-dose comparison of salbutamol and Duovent-Berodual in asthma. Respiration 1986; 50 (suppl.2): 285-289.

17. Eschenbacher W.L., Boushey H.A., Sheppard D. Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone. Am. Rev. Respir. Dis. 1984; 129: 211-215.

18. FitzGerald J.M., Grunfeld A., Pare P.D. et al. The clinical efficacy of combination nebulized anticholinergic and adrenergic bronchodilators vs nebulized adrenergic bronchodilator alone in acute asthma. Canadian Combivent Study Group. Chest 1997; 111:311-315.

19. Garrett J.E., Town G.I., Rodwell P., Kelly A.M. Nebulized salbutamol with and without ipratropium bromide in the treatment of acute asthma. J. Allergy Clin. Immunol. 1997; 100: 165-170.

20. Global strategy for asthma management and prevention NHLBI/WHO Workshop Report: NIH Publication No 02-3659. The 2002 report is available on www.ginasthma.com.

21. Gross N. Ipratropium bromide. N. Engl. J. Med. 1988; 319- 486-494.

22. Higgins R.M., Stradling J.R., Lane D.J. Should ipratropium bromide be added to beta-agonists in treatment of acute severe asthma? Chest 1988; 94: 718-722.

23. Jolobe O.M.P. Asthma versus non-specific reversible airflow obstruction: clinical features and responsiveness to anticholinergic drugs. Respiration 1984; 45: 237-242.

24. Karpel J.P., Pesin J., Greenberg D., Gentry E. A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD. Chest 1990; 98: 835-839.

25. Karpel J.P., Schacter E.N., Fanta C. et al. A comparison of ipratropium and albuterol vs albuterol for the treatment of acute severe asthma. Ibid. 1996; 110: 611-616.

26. Lanes S.F., Garrett J.E., Wentworth C.E. et al. The effect of adding ipratropium bromide to salbutamol in the treatment of acute asthma: a pooled analysis of three trials. Ibid. 1998; 114: 365-372.

27. Lin R.Y., Pesola G.R., Bakalchuk L. et al. Superiority of ipratropium plus albuterol over albuterol alone in the emergency department management of adult asthma: a randomized clinical trial. Ann. Emerg. Med. 1998; 31: 208-213.

28. Louw S.J., Goldin J.G., Isaacs S. Relative efficacy of nebulised ipratropium bromide and fenoterol in acute severe asthma. S. Afr. Med. J. 1990; 77: 24-26.

29. Lowry R., Wood A., Johnson T., Higenbottam T. Antitussive properties of inhaled bronchodilators on induced cough. Chest 1988; 93: 1186-1189.

30. Mazzei J.A., Torres J. Blind randomized cross-over comparative study of salbutamol and the combination fenoterol-ipratropium IK6 in patients with bronchial asthma. Respiration 1986; 50 (suppl.2): 313-317.

31. Morrison J.F., Pearson S.B., Dean H.G. Parasympathetic nervous system in nocturnal asthma. Br. Med. J. 1988; 296: 1427-1429.

32. Newnham D.M. Asthma medications and their potential adverse effects in the elderly: recommendations for prescribing. Drug Saf 2001; 24: 1065-1080.

33. O'Driscoll B.R., Taylor R.J., Horsley M.G. et al. Nebulized salbutamol with and without ipratropium bromide in acute airflow obstruction. Lancet 1989; 1: 1418-1420.

34. Ohrui T., Yanai M., Sekizawa K. et al. Effective site of bron- chodilation by beta-adrenergic and anticholinergic agents in patients with chronic obstructive pulmonary disease: direct measurement of intrabronchial pressure with a new catheter. Am. Rev. Respir. Dis. 1992; 146: 88-91.

35. Osmond M.H., Klassen T.P. Efficacy of ipratropium bromide in acute childhood asthma: a meta-analysis. Acad. Emerg. Med. 1995; 2: 651-656.

36. Philip-Joet F., Reynaud-Gaubert M., Jirou-Najou J.L., Arnaud A. Comparison of Berodual and salbutamol in asthma: a multicenter evaluation. Respiration 1990; 57: 379-383.

37. Plotnick L.H., Ducharme F.M. Should inhaled anticholinergics be added to beta2-agonists for treating acute childhood and adolescent asthma? A systematic review. Br. Med. J. 1998; 317: 971-977.

38. Plotnick L.H., Ducharme F.M. Combined inhaled anticholinergics and beta2-agonists for initial treatment of acute asthma in children (Cochrane Review). In: The Cochrane Library. Oxford, UK; 2002. Issue 2.

39. Rebuck A.S., Chapman K.R., Abboud R. et al. Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room. Am. J. Med. 1987; 82: 59-64.

40. Rennard S.I. Combination bronchodilator therapy in COPD. Chest 1995; 107 (suppl): 171S-175S.

41. Rennard S.I., Serby C.W., Ghafouri M. et al. Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. Ibid. 1996; 110: 62 - 70.

42. Rodrigo G.J., Rodrigo C., Burschtin 0. A meta-analysis of the effects of ipratropium bromide in adults with acute asthma. Am. J. Med. 1999; 107: 363-370.

43. Rodrigo G.J., Rodrigo C. First-line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in the emergency department. Am. J. Respir. Crit. Care Med. 2000; 161: 1862-1868.

44. Rodrigo G.J., Rodrigo C. The role of anticholinergics in acute asthma treatment: an evidence-based evaluation. Chest 2002; 121: 1977-1987.

45. Sheppard D., Rizk N.W., Boushey H.A. et al. Mechanism of cough and bronchoconstriction induced by distilled water aerosol. Am. Rev. Respir. Dis. 1983; 127: 691-694.

46. Stoodley R.G., Aaron S.D., Dales R.E. The role of ipratropium bromide in the emergency management of acute asthma exacerbation: a meta-analysis of randomized clinical trials. Ann. Emerg. Med. 1999; 34: 8-18

47. Summers Q.A., Tarala R.A. Nebulized ipratropium in the treatment of acute asthma. Chest 1990; 97: 425-429.

48. Sunyer J., Basagana X., Belmonte J., Anto J.M. Effect of nitrogen dioxide and ozone on the risk of dying in patients with severe asthma. Thorax 2002; 57: 687-693.

49. Tang O.T., Flatley M. A comparison of effects of inhaling a combined preparation of fenoterol with ipratropium bromide (Duovent) with those of fenoterol and salbutamol. Postgrad. Med. J. 1984; 60 (suppl.l): 24-27.

50. Tashkin D.P. Multiple dose regimens. Impact on compliance. Chest 1995; 107 (suppl.): 176S-182S.

51. Ullach M.I., Newman G.B., Saunders K.B. Influence of age on response to ipratropium and salbutamol in asthma. Thorax 1981; 36: 523-529.

52. Van Schayck C.P., Folgering H., Harbers H. et al. Effects of allergy and age on responses to salbutamol and ipratropium bromide in moderate asthma and chronic bronchitis. Ibid 1991; 46: 355-359.

53. Ward M.J. The role of anticholinergic drugs in acute asthma. In: Gross N., ed. Anticholinergic therapy in obstructive lung disease. London: Franklin Scientific Publication; 1993: 155-162.

54. Weber E.J., Levitt M.A., Covington J.K., Gambrioli E. Effect of continuously nebulized ipratropium bromide plus albuterol on emergency department length of stay and hospital admission rates in patients with acute bronchospasm: a randomized, controlled trial. Chest 1999; 115: 937-944.

55. Wolstenholme R.J., Shettar S.P. Comparison of a combination of fenoterol with ipratropium bromide (Duovent) and salbutamol in young adults with nocturnal asthma. Respiration 1989; 55: 152-157.

56. Yanai М., Ohrui T. et al. Effective site of bronchodilation by antiasthma drugs in subjects with asthma. J. Allergy Clin. Immunol. 1991; 87: 1080-1087.

57. Yao W., Wang G., Zhu H. et al. Effect of ipratropium bromide on airway and pulmonary muscarinic receptors in a rat model of chronic obstructive pulmonary disease. Chin. Med. J. (Engl.) 2001; 114: 80-83.